Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Liver Diseases

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 38 articles:
HTML format
Text format



Single Articles


    June 2017
  1. KASUYA G, Kato H, Yasuda S, Tsuji H, et al
    Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials.
    Cancer. 2017 Jun 29. doi: 10.1002/cncr.30816.
    PubMed     Text format     Abstract available


  2. LIN YY, Yu MW, Lin SM, Lee SD, et al
    Genome-wide association analysis identifies a GLUL haplotype for familial hepatitis B virus-related hepatocellular carcinoma.
    Cancer. 2017 Jun 29. doi: 10.1002/cncr.30851.
    PubMed     Text format     Abstract available


  3. PARIKH ND, Singal AG, Hutton DW
    Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.
    Cancer. 2017 Jun 29. doi: 10.1002/cncr.30863.
    PubMed     Text format     Abstract available


  4. CHAN SL, Yeo W, Mo F, Chan AWH, et al
    A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma.
    Cancer. 2017 Jun 22. doi: 10.1002/cncr.30825.
    PubMed     Text format     Abstract available


    May 2017
  5. TARHINI AA, Rafique I, Floros T, Tran P, et al
    Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
    Cancer. 2017 May 4. doi: 10.1002/cncr.30717.
    PubMed     Text format     Abstract available


    April 2017
  6. ZHOU H, Guo M, Gong Y
    Challenge of FNA diagnosis of angiomyolipoma: A study of 33 cases.
    Cancer. 2017;125:257-266.
    PubMed     Text format     Abstract available


    February 2017
  7. KATZENSTEIN HM, Furman WL, Malogolowkin MH, Krailo MD, et al
    Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee.
    Cancer. 2017 Feb 17. doi: 10.1002/cncr.30591.
    PubMed     Text format     Abstract available


  8. FRANKEL TL, Vakiani E, Nathan H, DeMatteo RP, et al
    Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.
    Cancer. 2017;123:568-575.
    PubMed     Text format     Abstract available


  9. SAHLMANN CO, Homayounfar K, Niessner M, Dyczkowski J, et al
    Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: Safety, feasibility, and long-term efficacy results of a prospective phase 2 study.
    Cancer. 2017;123:638-649.
    PubMed     Text format     Abstract available


    January 2017
  10. MANCUSO A
    Management of hepatocellular carcinoma in thalassemia and importance of the human factor.
    Cancer. 2017 Jan 13. doi: 10.1002/cncr.30551.
    PubMed     Text format    


  11. MOUKHADDER HM, Halawi R, Cappellini MD, Taher AT, et al
    Reply to Management of hepatocellular carcinoma in thalassemia and importance of the human factor.
    Cancer. 2017 Jan 13. doi: 10.1002/cncr.30550.
    PubMed     Text format    


  12. KUTLU OC, Chan JA, Aloia TA, Chun YS, et al
    Comparative effectiveness of first-line radiofrequency ablation versus surgical resection and transplantation for patients with early hepatocellular carcinoma.
    Cancer. 2017 Jan 13. doi: 10.1002/cncr.30531.
    PubMed     Text format     Abstract available


  13. LAMARCA A, Pihlak R, Frizziero M, McNamara MG, et al
    Elderly patients diagnosed with hepatopancreatobiliary malignancies: A challenge beyond resection.
    Cancer. 2017 Jan 6. doi: 10.1002/cncr.30502.
    PubMed     Text format    


  14. MARMOR S, Burke EE, Virnig BA, Jensen EH, et al
    Reply to Elderly patients diagnosed with hepatopancreatobiliary malignancies: A challenge beyond resection.
    Cancer. 2017 Jan 6. doi: 10.1002/cncr.30500.
    PubMed     Text format    


    December 2016
  15. YAMASHITA S, Koay EJ, Passot G, Shroff R, et al
    Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients.
    Cancer. 2016 Dec 16. doi: 10.1002/cncr.30488.
    PubMed     Text format     Abstract available


  16. MOUKHADDER HM, Halawi R, Cappellini MD, Taher AT, et al
    Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: A comprehensive review.
    Cancer. 2016 Dec 1. doi: 10.1002/cncr.30462.
    PubMed     Text format     Abstract available


    October 2016
  17. PONZETTO A, Figura N
    High hepatocellular carcinoma risk among US-born Hispanics.
    Cancer. 2016 Oct 14. doi: 10.1002/cncr.30397.
    PubMed     Text format    


  18. SETIAWAN VW, Wei PC, Hernandez BY, Lu SC, et al
    Reply to high hepatocellular carcinoma risk among US-born Hispanics.
    Cancer. 2016 Oct 14. doi: 10.1002/cncr.30396.
    PubMed     Text format    


    September 2016
  19. LORIOT Y, Fizazi K, de Bono JS, Forer D, et al
    Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.
    Cancer. 2016 Sep 20. doi: 10.1002/cncr.30336.
    PubMed     Text format     Abstract available


  20. CHOO SP, Tan WL, Goh BK, Tai WM, et al
    Comparison of hepatocellular carcinoma in Eastern versus Western populations.
    Cancer. 2016 Sep 13. doi: 10.1002/cncr.30237.
    PubMed     Text format     Abstract available


    August 2016
  21. YANG JD, Altekruse SF, Nguyen MH, Gores GJ, et al
    Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States.
    Cancer. 2016 Aug 29. doi: 10.1002/cncr.30246.
    PubMed     Text format     Abstract available


  22. SHOUSHTARI AN, Munhoz RR, Kuk D, Ott PA, et al
    The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
    Cancer. 2016 Aug 17. doi: 10.1002/cncr.30259.
    PubMed     Text format     Abstract available


    July 2016
  23. CRANE CH, Koay EJ
    Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance.
    Cancer. 2016;122:1974-86.
    PubMed     Text format     Abstract available


    June 2016
  24. DROOGER JC, van Tinteren H, de Groot SM, Ten Tije AJ, et al
    A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
    Cancer. 2016 Jun 17. doi: 10.1002/cncr.30141.
    PubMed     Text format     Abstract available


    May 2016
  25. SINGAL AG, Yopp AC
    Hepatocellular carcinoma: How can we move from racial/ethnic disparities to a model of health equity?
    Cancer. 2016 May 19. doi: 10.1002/cncr.30099.
    PubMed     Text format    


  26. HA J, Yan M, Aguilar M, Bhuket T, et al
    Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States.
    Cancer. 2016 May 19. doi: 10.1002/cncr.30103.
    PubMed     Text format     Abstract available


  27. NAKAMURA T, Matsumine A, Kawai A, Araki N, et al
    The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
    Cancer. 2016;122:1408-16.
    PubMed     Text format     Abstract available


    April 2016
  28. TAKEDA A, Sanuki N, Tsurugai Y, Iwabuchi S, et al
    Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation.
    Cancer. 2016 Apr 8. doi: 10.1002/cncr.30008.
    PubMed     Text format     Abstract available


    March 2016
  29. MAKAROVA-RUSHER OV, Altekruse SF, McNeel TS, Ulahannan S, et al
    Population attributable fractions of risk factors for hepatocellular carcinoma in the United States.
    Cancer. 2016 Mar 21. doi: 10.1002/cncr.29971.
    PubMed     Text format     Abstract available


  30. RYERSON AB, Eheman CR, Altekruse SF, Ward JW, et al
    Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.
    Cancer. 2016 Mar 9. doi: 10.1002/cncr.29936.
    PubMed     Text format     Abstract available


  31. MOR V, Joyce NR, Cote DL, Gidwani RA, et al
    The rise of concurrent care for veterans with advanced cancer at the end of life.
    Cancer. 2016;122:782-90.
    PubMed     Text format     Abstract available


    February 2016
  32. DEPERALTA DK, Wei L, Ghoshal S, Schmidt B, et al
    Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis.
    Cancer. 2016 Feb 23. doi: 10.1002/cncr.29912.
    PubMed     Text format     Abstract available


    January 2016
  33. ESNAOLA NF, Meyer JE, Karachristos A, Maranki JL, et al
    Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma.
    Cancer. 2016 Jan 22. doi: 10.1002/cncr.29692.
    PubMed     Text format     Abstract available


    December 2015
  34. TAPPER EB, Catana AM, Sethi N, Mansuri D, et al
    Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis.
    Cancer. 2015 Dec 30. doi: 10.1002/cncr.29855.
    PubMed     Text format     Abstract available


  35. KONSTANTINIDIS IT, Koerkamp BG, Do RK, Gonen M, et al
    Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.
    Cancer. 2015 Dec 22. doi: 10.1002/cncr.29824.
    PubMed     Text format     Abstract available


  36. STEUER CE, Behera M, Berry L, Kim S, et al
    Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
    Cancer. 2015 Dec 22. doi: 10.1002/cncr.29812.
    PubMed     Text format     Abstract available


    October 2015
  37. MARTIN RC 2ND, Scoggins CR, Schreeder M, Rilling WS, et al
    Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
    Cancer. 2015;121:3649-58.
    PubMed     Text format     Abstract available


    September 2015
  38. BISHOP AJ, Ensor J, Moulder SL, Shaitelman SF, et al
    Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy.
    Cancer. 2015 Sep 8. doi: 10.1002/cncr.29681.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: